Fibromyalgia Treatment Market

Global fibromyalgia treatment market is estimated to be valued at USD 3.07 BN in 2024 and is expected to exhibit a CAGR of 3.3% during the forecast period (2024-2031). Fibromyalgia is a disorder characterized by chronic widespread pain and tenderness in the muscles, ligaments and tendons. It is often accompanied by fatigue, sleep issues, memory and mood issues. The exact cause of fibromyalgia is still unknown but is believed to be due to neurochemical imbalance in the brain. The symptoms negatively impact quality of life of those suffering from it. Currently there is no cure for fibromyalgia but the treatment aims to manage symptoms and improve day to day functioning. Some of the common treatment options include medications, lifestyle changes, alternate therapies, cognitive behavior therapy etc. The global fibromyalgia treatment market is expected to witness significant growth due to the increasing diagnosis rates and growing awareness about the condition.

Market Dynamics:

The global fibromyalgia treatment market is driven by the rising prevalence of fibromyalgia worldwide. As per estimates, fibromyalgia affects about 2-8% of the global population. Moreover, increasing approval of new drug formulations for fibromyalgia treatment is also boosting the market growth. However, high cost of treatment therapies and lack of cure hinders the market potential. Lack of awareness among physicians also poses a challenge. The market players have opportunities to develop novel drug formulations for fibromyalgia cure and offer treatment options at affordable prices. Increasing adoption of biologics also opens new growth avenues.

Key Features of the Study:

• This report provides in-depth analysis of the global fibromyalgia treatment market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global fibromyalgia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Eli Lilly and Company, Pfizer Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx Inc., Prismic Pharmaceuticals Inc., Innovative Med Concepts Inc., Intec Pharma Ltd., Astellas Pharma Inc., Johnson & Johnson, GSK, AstraZeneca plc, Bristol Myers Squibb, Viatris, Takeda Pharmaceutical Company Limited, Amgen Inc., and Sanofi.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibromyalgia treatment market.

Market Segmentation

• Drug Class:
  • Antidepressants 
  • Antiepileptics 
  • Muscle Relaxants
  • Analgesics
  • Others 
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 
• Regional:            
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eli Lilly and Company
  • Pfizer Inc.
  • Novartis AG
  • Allergan plc
  • Sun Pharmaceutical Industries Ltd.
  • Aptinyx Inc.
  • Prismic Pharmaceuticals Inc.
  • Innovative Med Concepts Inc.
  • Intec Pharma Ltd.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • GSK
  • AstraZeneca plc
  • Bristol Myers Squibb
  • Viatris
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Sanofi